Compare LFMDP & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMDP | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 336 | 1300 |
| Industry | Medical/Nursing Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | LFMDP | WGSWW |
|---|---|---|
| Price | $22.78 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5K | ★ 62.5K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | $18.50 | $0.01 |
| 52 Week High | $26.99 | $0.25 |
| Indicator | LFMDP | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 33.30 |
| Support Level | $22.03 | $0.01 |
| Resistance Level | $22.84 | $0.02 |
| Average True Range (ATR) | 0.21 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 47.78 | 18.24 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.